To this end, we evaluated and compared ex vivo binding of the GRPR- and PSMA-targeting radiopharmaceuticals [177Lu]Lu-NeoB and [177Lu]Lu-PSMA-617, respectively, to patient tissue sections obtained from benign prostatic hyperplasia (BPH), primary PCa and progressive CRPC lesions. Here, FOLH1 is linked to benign prostatic hyperplasia.